CA209-649 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (Aktiv)
COMPETE Eine prospektive, randomisierte, kontrollierte, offene, multizentrische Phase III Studie zur Beurteilung der Wirksamkeit und Sicherheit der Peptid-Rezeptor-Radionuklid-Therapie (PRRT) mit 177Lutetium-Edotreotid im Vergleich zur gezielten molekularen Therapie mit Everolimus bei Patienten mit inoperablen, progressiven, Somatostatin-Rezeptor positiven (SSTR +), neuroendokrinen Tumoren des Magen-Darm Trakts oder pankreatischen Ursprungs (GEP-NET) (Aktiv)
FLOT5 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5) (Aktiv)
MK7902-015 Eine randomisierte Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapie im Vergleich zur Standardtherapie als Erstlinienintervention bei Teilnehmern mit fortgeschrittenem/metastasierendem gastroösophagealem Adenokarzinom (LEAP-015) (Aktiv)
OPPOSITE Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen. (Aktiv)
Polestar Phase II Studie zu Pembrolizumab und Olaparib als Erstlinientherapie bei Her2- negativem Adenokarzinom des Magens/gastroösophagealen Übergangs (Aktiv)
SPOT Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus (Aktiv)
Zweitlinie oder später
AIO-STO-0218 Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma (AIO-STO-0218) (Aktiv)
AMG 199 Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer (Aktiv)
AMG910 Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (Aktiv)
CVPM087A2101 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (Aktiv)
Destiny 03 Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (Aktiv)
EORTC Vestige Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) (Aktiv)
FLOT 9 HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) (Aktiv)
I4T-NS-O038 - RE-ExPEL Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (Aktiv)
LIBRETTO-001 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)
MSD MK3475-975 Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) (Aktiv)
RACE Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ (Aktiv)
RAMIRIS_AIO STO 0415 Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Gastric Cancer (Aktiv)